CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise.
UBS analyst Eliana Merle upgraded the shares (ticker: CVAC) to Buy from Neutral and raised her 12-month target for the stocks price to $18 from $8 on Thursday. Merle listed recent clinical trial data and the biopharmaceutical company’s ability to gain market share as reasons for the upgrade.
Source: finance.yahoo.com
Related posts:
What Is the Roth IRA 5-Year Rule?
10 defensive stocks that can also provide you with growth and dividends over the long term
Deposits dropped at regional banks USB and CFG during 1Q tumult
Only Fund Beating Nasdaq Long-Term Is Defying Stock-Picking Odds
6 Inexpensive Consumer Stocks With Strong Profit Growth